Survival and safety of treatment with infliximab in the elderly population [8]

Rheumatology

Volumn 44, Issue 5, 2005, Pages 695-696

  Chevillotte Maillard, H ^a   Ornetti, P ^a   Mistrih, R ^a   Sidot, C ^b   Dupuis, J ^c   Dellas, J A ^d   Tavernier, C ^a   Maillefert, Jean Francis ^a,e,f  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b Department of Medicine and Rheumatology   (France)

^c HÔTEL DIEU   (France)

^d G Ramon Hospital   (France)

^e UNIVERSITÉ DE BOURGOGNE   (France)

^f HÔPITAL DU BOCAGE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR DECOY RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR-ALPHA INHIBITOR; TUMOR PROTEIN;

ADULT; AGED; ANALYSIS OF VARIANCE; ANKYLOSING SPONDYLITIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEMALE; FISHER EXACT TEST; HUMAN; INFECTION; LETTER; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SURVIVAL TIME; AGE; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR DECOY RECEPTORS;

EID: 21244441940     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keh562     Document Type: Letter

References (10)

1. Day R. Adverse reactions to TNF-alpha inhibitors in rheumatoid arthritis. Lancet 2002;359:540-1.
2. Weisman MH. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. J Rheumatol 2002; 29(Suppl. 65):33-8.
3. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicentre-active surveillance report. Arthritis Rheum 2003; 48:2122-7
4. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology 2003;42:617-21.
5. Hyrich KL, Silman AL, Watson KD, Symmons DPM. Anti-tumour necrosis factor α therapy in rheumatoid arthritis: An update on safety. Ann Rheum Dis 2004;63:1538-43.
6. Maillard H, Ornetti P, Grimault L et al. Severe pyogenic infections in patients treated with infliximab. Joint Bone Spine (in press).
7. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis. 2002 update. Arthritis Rheum 2002;46:328-46.
8. Ledingham J, Deighton C, on behalf of the BSR Standards, Guidelines and Audit Working Group. Update of the BSR guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. http://www.rheumatology.org.uk
9. Cairns A, Taggart A. Anti-tumour necrosis factor therapy for severe inflammatory arthritis: Two years of experience in Northern Ireland. Ulster Med J 2002;71:101-5.
10. Furst DE. Observational cohort studies and well controlled clinical trials - we need them both! J Rheumatol 2004;31:1476-7.